PharmaFlair Introduces new Franchise segments for Business in Derma, Ayurveda, Cardiac-Diabetic & Pediatrics in 2020

PharmaFlair - B2B Marketplace has listed new Business categories for Pharma Franchise ranging from Derma & Cosmetics, Ayurveda, Ophthalmic, Cardiac-Diabetic, Orthopedics, Pediatrics, Gynae, etc. for PCD Pharma Franchise Suppliers & Seekers in India.
Feb 18, 2020 Mark

Press Release (ePRNews.com) - Chandigarh, India - Feb 18, 2020 - PharmaFlair an online B2B Platform for the Pharma product & service providers like Pharma Manufacturers, Pharma Wholesale licensed Traders, Contract Manufacturers & PCD Pharma Franchise Suppliers based in India or Globally.  PharmaFlair bridges the gap between Pharma, Healthcare & Medical Product Suppliers & Buyers, help its users to connect with Verified product & service providers. PharmaFlair initially were offering Business Listing for Pharma Companies deals in Antibiotics, ENT products, Anti Cancer Drugs, Allopathics, Analgesics, NASAID, Anti Ineffective Medicine, Anti Cold & Cough, Anti Allergic medicine, Veterinary, etc. and providing Franchise to Opportunity seekers on a monopoly basis.

Pharmaceutical Industry is growing at CAGR of 15% and is expected to reach USD 250 billion by 2020. Investing in Pharma Franchise is considered profitable by pharma experts. PharmaFlair ‘B2B Pharmaceutical Business Portal’ by understanding the landscape has introduced new Pharma Franchise Business categories which are mostly preferred by Pharma Investors & professionals due to increasing demand in the market. Pharma Franchise business acts as a bridge between the pharmaceutical companies and patients, thus, growth of the pharmaceutical industry means the growth of Pharma Franchise business. PharmaFlair has Introduced new Pharma Franchise segments for Business in Derma, Ayurveda, Ophthalmic & Pediatrics Range in 2020.

Dermatology & Cosmetics Range

Skin-related ailments, or dermatology, is making its presence felt in the domestic market over the last three years with Rs 8,700 crore market in India. Derma Product Manufacturers in India now can reach to thousand of franchise seeker’s by listing their full fledged range of Derma & Cosmetics for PCD Pharma Franchise.

 

Cardiac and Diabetes Drugs

Cardiac and diabetes drugs are under-penetrated therapy areas, and are expected to grow at a more faster pace for Diabetic Drug from 12.6% and 11.7% Cardiac Medicine growth rate in India. PharmaFlair has opened the Pharma Franchise for Cardiac & Diabetic medicines with 52 new brands of anti-diabetes drugs were launched in December after the expiry of Novartis’ patent on vildagliptin.

 

Gynecology Drugs 

Gynaecology Drug market is growing at CAGR of 8.2% and having 0.95% of Market share over other medicine segments in India. Pharma Professionals looking to invest in Pharma Franchise for Gynaecology Drugs now can connect with Pharma Manufacturers & traders deals in Gynae & Infertility product range.

 

With the Vision 2020, PharmaFlair is heading towards finding a spot in the World’s Top B2B Pharma Marketplace exclusively for the Pharmaceutical, Medical & Healthcare Industry. This business portal currently has 700+ pharma companies registered with their own or third party manufacturing facilities with over 50,000+ products ranging in all categories like Pharma Tablets, Capsules, Injections, Syrups, Powders, Ointments, Sachet, Injection, etc.

Source : PharmaFlair - B2B Pharma Marketplace Follow on Google News
Business Info :
PharmaFlair
SCO:89, F.F. Sector - 5, MDC, Panchkula
134114
Phone: 7087772935
Website: https://pharmaflair.in
CATEGORIES : Franchising Health
SHARE :  

Login

Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Already have an account ? Login

Reset Password

Already have an account ? Login

DISCLAIMER

If you have any concerns regarding this press release, please contact the Author / Media Contact / Business of this press release. ePRNews is not resposible for the accuracy of the news posted and do not endorse, support any product/ services/ business mentioned and hereby disclaims any content contained in this press release.